Gopinath Vedachalam Annathur,Palani Balu,Rory Francis Finn,Jie Huang,Olivier Alexandre Laurent,Nancy Jane Levin,Nicholas Gary Luksha,Joseph Patrick Martin, Jr.,Haim Moskowitz,Moorthy Sitharamaiah Suri
申请号：
US13712873
公开号：
US09163227B2
申请日:
2012.12.12
申请国别(地区):
US
年份:
2015
代理人:
摘要：
The present invention provides a composition of the formula: [FGF21-1st Linker]-[Ab]-[2nd-Linker-Ex4]； wherein FGF21 is an FGF21 homologue； and Ex4 is an Exendin4 homologue； and Ab is an aldolase catalytic antibody or antigen binding portion thereof； and the 1st linker is covalently attached to the side chain of a protein-linking residue in FGF21 and to a combining site of the antibody, and the 2nd linker is covalently attached to the side chain of a peptide-linking residue in Ex4 and to a combining site of the antibody, and wherein the first and second linker are the same or different. Various uses of the compounds are provided, including methods to prevent or treat diabetes or diabetes-related conditions.
